Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
Status:
Completed
Trial end date:
2017-07-30
Target enrollment:
Participant gender:
Summary
Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From
patients with ischemic heart disease, we know that patients with in vitro high on treatment
platelet reactivity (HTPR) have an increased risk of stent thrombosis following per-cutaneous
coronary intervention. Other studies have shown association of CYP2C19 genotypes with
different responses to the anti platelet drug Clopidogrel. We measure HTPR in ischemic stroke
patients on increasing doses of clopidogrel and investigate the CYP2C19 genotype for each
patient.